Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicaid Outcomes-Based Payment Model For Cell, Gene Therapy to Launch In 2025

Executive Summary

But CMMI does not yet have a launch date for the proposed Medicare demonstration on drugs cleared through FDA’s accelerated approval pathway and the demonstration allowing Part D plans to offer certain high-value generics with a $2 beneficiary copay.

You may also be interested in...

Medicaid Payments For Cell, Gene Therapies Outside Hospital Bundle Supported By Developers

Separate, and higher, payments outside the bundle means manufacturers will owe Medicaid rebates, and that is OK, Alliance for Regenerative Medicine tells Sen. Cassidy. But manufacturers want assurances they won't be liable for rebates on treatments included in bundled payments.

Sickle Cell Gene Therapy Reimbursement: Will Experience Matter? And Which Kind?

The tandem launches of two gene therapies for sickle cell disease will likely be critical to determining whether and how US reimbursement policies can shape commercial success for hugely expensive, one-time treatments. Bluebird is the smaller, less-experienced company up against Vertex – but argues it has more relevant experience.

Sickle Cell Gene Therapy Uptake May Lag, But Still Shock State Medicaid Budgets

Medicaid state programs, expected to be the majority payers for the new gene therapies, lack certain flexibilities to help them quickly adapt to high-priced treatments, particularly given the huge jump from current sickle cell treatment costs to the just-approved breakthroughs.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts